Beactica Therapeutics initiates IND-enabling studies for glioblastoma drug

Swedish precision medicine company Beactica Therapeutics AB announced the initiation of IND-enabling studies for its wholly owned drug candidate, BEA-17. This program moves the compound from preclinical proof-of-concept toward the formal safety, manufacturing, and regulatory processes required for human testing.

BEA-17 is being developed as a precision immunotherapy for glioblastoma (GBM). It is designed as a first-in-class oral degrader targeting the epigenetic regulators LSD1 and CoREST.

The IND-enabling studies are critical for obtaining regulatory approval to begin clinical trials. These studies will assess the drug's safety profile, manufacturing scalability, and ensure compliance with requirements for both Clinical Trial Applications (CTA) in the EU and Investigational New Drug (IND) applications in the US.

Successful completion of these studies will pave the way for Beactica Therapeutics to initiate first-in-human clinical trials, marking a significant step in the development of a potential new treatment for glioblastoma.